Gilead Sciences Inc (GILD): Today's Featured Health Care Loser
Gilead (GILD) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day down 1.7%. By the end of trading, Gilead fell $1.12 (-2.2%) to $50.27 on light volume. Throughout the day, 5.6 million shares of Gilead exchanged hands as compared to its average daily volume of 9.2 million shares. The stock ranged in price between $50.19-$51.09 after having opened the day at $50.86 as compared to the previous trading day's close of $51.39. Other company's within the Health Care sector that declined today were: Synergy Pharmaceuticals (SGYP), down 20.9%, Alexza Pharmaceuticals (ALXA), down 19.7%, Anika Therapeutics (ANIK), down 17%, and Cadence Pharmaceuticals (CADX), down 16.7%. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. Gilead has a market cap of $39.31 billion and is part of the drugs industry. The company has a P/E ratio of 14.5, below the average drugs industry P/E ratio of 15.5 and below the S&P 500 P/E ratio of 17.7. Shares are up 25.6% year to date as of the close of trading on Thursday. Currently there are 20 analysts that rate Gilead a buy, no analysts rate it a sell, and five rate it a hold. TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Gilead Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Latest Headlines about GILD
-
Cramer's Top Stock Picks: SAVE GILD BMY HTA TSLA
06:00AM 05/21/13
-
Quick Take: The Next Big Thing in Biotech
10:44AM 05/17/13
-
'Mad Money' Lightning Round: Magnum Hunter Blew It
06:00AM 05/17/13
-
Cramer's 'Mad Money' Recap: Step Aside, Chicken Little
08:21PM 05/16/13
-
ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up
06:00PM 05/15/13
-
ASCO '13 Preview: Gilead's Big Cancer Debut
06:00PM 05/15/13
-
Cramer: Biotech Makes a Comeback
04:39PM 05/10/13
Latest from TheStreet Wire
-
Dow Today: Boeing (BA) Higher
02:00PM 05/23/13
-
Dover Rises On Unusually High Volume (DOV)
01:54PM 05/23/13
-
Today's Stocks Driving Success For The Health Services Industry
01:03PM 05/23/13
-
CTRX, STJ, CI, TMO And BAX, Pushing Health Services Industry Downward
01:03PM 05/23/13
-
5 Stocks Underperforming Today In The Services Sector
01:03PM 05/23/13
-
3 Stocks Advancing The Energy Industry
01:03PM 05/23/13
-
4 Stocks Moving The Consumer Non-Durables Industry Upward
01:03PM 05/23/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
